Description
Rociletinib is a third-generation irreversible kinase inhibitor of epidermal growth factor receptor (EGFR). Rociletinib was shown to inhibit the proliferation of non-small cell lung cancer (NSCLC) cells expressing mutant EGFR. It also exhibits anti-tumor activity in NSCLC EGFR mutant xenograft models